The rationale for combining antimitotic inhibition with Cetuximab, an EGFR inhibitor, to enhance the death of oral cancer cells is based on the complementary roles these proteins play in cell proliferation and survival. This evidence concerns the gene EGFR and lip and oral cavity carcinoma.